Will the medical insurance price of osimertinib change in 2025?

Osimertinib is a third-generation EGFR tyrosine kinase inhibitor. It is mainly used to treat patients with EGFR mutation-positive non-small cell lung cancer. It is especially effective against T790M drug-resistant mutations. The drug has received widespread attention since its introduction into the Chinese market. In 2025, osimertinib will still be included in the national medical insurance directory, and the continued guarantee of medical insurance coverage will reduce the financial burden on patients. At present, the medical insurance payment price for 80mg*30 tablets is about five to six thousand yuan, which has dropped significantly compared with the high price before it was included in medical insurance.

According to the latest medical insurance policy adjustment information in2025, the medical insurance payment standard of osimertinib has not increased significantly and the price remains stable. This is mainly due to the state's centralized bulk procurement and pharmaceutical companies' continued participation in the medical insurance negotiation mechanism, which has rationalized price control for key tumor-targeted drugs. Although the price of original drugs is still not low, most patients can afford it after paying for it through medical insurance. Especially when purchasing drugs in tertiary hospitals and major public medical institutions, you can directly enjoy the medical insurance reimbursement policy.

At the same time, there are also some more affordable imitation versions available on the market. For example, the generic drugs of Osimertinib produced in Laos and Bangladesh have been launched through formal channels. The active ingredients of these generic drugs are consistent with the original drugs. The price of 80mg*30 tablets is only a few hundred yuan, which is suitable for patients who are not covered by medical insurance or who are paying for treatment outside medical insurance. However, although generic drugs have obvious price advantages, when purchasing drugs, you should pay attention to the formality of the source of the drugs to ensure efficacy and safety.

Overall, The medical insurance price of osimertinib remains stable in 2025, and its continued inclusion in medical insurance provides treatment protection for the majority of domestic non-small cell lung cancer patients. For patients covered by medical insurance, it is recommended to give priority to obtaining original drugs through formal medical channels and enjoy the medical insurance reimbursement policy; while patients with limited financial conditions or unable to purchase through medical insurance channels in time can choose overseas generic versions with reliable quality under the guidance of doctors. During the medication process, standardized treatment and regular review should be adhered to to improve the quality of life and treatment effect.

Reference materials:https://go.drugbank.com/drugs/DB09330